Phosphate restriction using a processed clay mineral reduces vascular pathologies and microalbuminuria in rats with chronic renal failure

• Published in: BMC nephrology 2022-04, Vol.23 (1), p.162-162, Article 162
• Main Authors: Hofrichter, Jacqueline, Sempert, Kai, Kerkhoff, Claus, Breitrück, Anne, Wasserkort, Reinhold, Mitzner, Steffen
• Format: Article
• Language: English
• Subjects: 5/6 Nephrectomy; Albuminuria - complications; Analysis; Animal models; Animals; Antibodies; Blood vessels; Calcium phosphates; Cardiovascular diseases; Care and treatment; Chronic Kidney Disease; Chronic kidney failure; Chronic Renal Failure; Clay; Clay Minerals; Collagen; Creatinine; Diagnosis; Diet; Dietary minerals; Female; Fibrosis; Glomerular filtration rate; Hemodialysis; Humans; Hyperphosphatemia; Kidney diseases; Kidney Failure, Chronic - complications; Kidney function tests; Lanthanum; Male; Minerals; Montmorillonite; Montmorillonite-Illite Clay Minerals; Morbidity; Mortality; Muscle contraction; Nephrectomy; Nephrology; Nutrient deficiency; Patient outcomes; Phenotypes; Phosphate; Phosphate Binder; Phosphates; Proteins; Proteinuria; Rats; Renal failure; Renal function; Renal Insufficiency, Chronic - complications; Risk factors; Rodents; Smooth muscle; Software; Uric acid; Urine
• ISSN: 1471-2369; 1471-2369
• DOI: 10.1186/s12882-022-02743-5

The progression of chronic kidney disease (CKD) is associated with an increasing risk of cardiovascular morbidity and mortality due to elevated serum phosphate levels. Besides low phosphate diets and hemodialysis, oral phosphate binders are prescribed to treat hyperphosphatemia in CKD patients. This study reports on a processed clay mineral as a novel and efficient phosphate sorbent with comparable efficacy of a clinically approved phosphate binder. 5/6 nephrectomized rats, which develop chronic renal failure (CRF), received a high phosphate and calcium diet supplemented with either a processed Montmorillonite-Illite clay mineral (pClM) or lanthanum carbonate (LaC) for 12 weeks. Levels of plasma uremic toxins, glomerular filtration rates and microalbuminuria were determined and the histomorphology of blood vessels and smooth muscle cells was analyzed. 5/6 nephrectomy induced an increase in plasma uremic toxins levels and progressive proteinuria. Treatment of CRF rats with pClM decreased observed vascular pathologies such as vascular fibrosis, especially in coronary vessels. The transition of vascular smooth muscle cells from a contractile to a secretory phenotype was delayed. Moreover, pClM administration resulted in decreased blood creatinine and urea levels, and increased glomerular filtration rates, reduced microalbuminuria and eventually the mortality rate in CRF rats. Our study reveals pClM as a potent phosphate binding agent with beneficial impacts on pathophysiological processes in an animal model of CKD. pClM effectively attenuates the progression of vascular damage and loss of renal function which are the most severe consequences of chronic renal failure.